Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-22
2007-05-22
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S224000, C544S336000, C546S184000, C546S192000, C546S193000, C546S194000
Reexamination Certificate
active
10414943
ABSTRACT:
Disclosed are novel compounds of the formulawherein R1is benzimidazolone derivative, M1and M2are optionally substituted carbon or nitrogen, R2includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1receptor antagonist.
REFERENCES:
patent: 5807865 (1998-09-01), Harrison et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 6211199 (2001-04-01), Kane et al.
patent: 2387613 (2001-05-01), None
patent: 63-227573 (1988-09-01), None
patent: 96/13262 (1996-05-01), None
patent: WO 98/06394 (1998-02-01), None
patent: 01/32649 (2001-05-01), None
patent: 02/24659 (2002-03-01), None
patent: WO 02/32893 (2002-04-01), None
patent: WO 02/072570 (2002-09-01), None
patent: 02/085890 (2002-10-01), None
“Abbott's H3 histamine receptor antagonist, ABT-239, a candidate treatment of cognitive disorders, ADHD, Alzheimer's and schizophrenia,” TherapeuticAdvances Lead Discovery's bulletin, www.leaddiscovery.co.uk, Jan. 2005, pp. 1-5.
Basic Clinical and Pharmacology, 7th edition, Bertram G. Katzung, pp. 268-269.
Henning et al.,Journal of Medicinal Chemistry, vol. 30, 1987, pp. 814-819.
Curtin et al.,Journal of Medicinal Chemistry, vol. 41 (1998) pp. 74-95.
Obase et al.,J. Heterocyclic Chemistry, vol. 20 (1983) pp. 565-573.
Rizzo et al.,European Journal of Pharmacology, vol. 294 (1995) pp. 329-335.
McLeod et al, Combined Histamine H1 and H3 . . . Am. J. Rhinology, 13, 5 (1999), p. 391-399.
Taylor-Clark et al, Histamine Receptors . . . , Brit J. Pharmacology, 144 (2005), p. 657-674.
Leura et al, Therapeutic potential of histamine . . . , TiPS, 19 (1998), p. 177-183.
Henning et al.,Journal of Medicinal Chemistry, vol. 30, 1987, pp. 814-819.
Curtain et al.,Journal of Medicinal Chemistry, vol. 41 (1998) pp. 74-95.
Obase et al.,J. Heterocyclic Chemistry, vol. 20 (1983) pp. 565-573.
Rizzo et al.,European Journal of Pharmacology, vol. 294 (1995) pp. 329-335.
U.S. Appl. No. 10/417,391.
U.S. Appl. No., filed Jun. 20, 2003, “Indole Derivatives Useful as Histamine H3Antagonists” (claims benefit of 60/390,987).
CA 137:337920, 2002:832786 (abstract of WO 02/085890).
Aslanian Robert G.
Berlin Michael Y.
Boyce Christopher W.
Cao Jianhua
Mangiaracina Pietro
Bergman Jeffrey P.
Johnsen Jason H.
Magatti Anita W.
Schering Corporation
Wilson James O.
LandOfFree
Benzimidazolone histamine H 3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazolone histamine H 3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazolone histamine H 3 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3815361